{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:32Z","timestamp":1761894992833,"version":"3.37.0"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/hjh.0b013e3283310f92","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T08:23:09Z","timestamp":1258446189000},"page":"2321-2331","source":"Crossref","is-referenced-by-count":24,"title":["Renal and cardio-protective effects of direct renin inhibition: a systematic literature review"],"prefix":"10.1097","volume":"27","author":[{"given":"Hiddo J","family":"Lambers Heerspink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210208","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00000441-200307000-00003","article-title":"The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states","volume":"326","author":"Brewster","year":"2003","journal-title":"Am J Med Sci"},{"key":"R2-3-20210208","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","article-title":"The cardiovascular continuum and renin-angiotensin-aldosterone system blockade","volume":"23","author":"Dzau","year":"2005","journal-title":"J Hypertens"},{"key":"R3-3-20210208","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.106.3.439","article-title":"The preparation, purification, and amino acid sequence of a polypeptide renin substrate","volume":"106","author":"Skeggs","year":"1957","journal-title":"J Exp Med"},{"key":"R4-3-20210208","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1016\/S0021-9258(17)39344-4","article-title":"Inhibition of human renin by synthetic peptides derived from its prosegment","volume":"260","author":"Cumin","year":"1985","journal-title":"J Biol Chem"},{"key":"R5-3-20210208","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/13543776.13.5.589","article-title":"Renin inhibitors as novel treatments for cardiovascular disease","volume":"13","author":"Maibaum","year":"2003","journal-title":"Expert Opinion Ther Patients"},{"key":"R6-3-20210208","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00005344-198908000-00006","article-title":"CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity","volume":"14","author":"Wood","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"R7-3-20210208","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0163-7258(94)90015-9","article-title":"Pharmacology of renin inhibitors and their application to the treatment of hypertension","volume":"61","author":"Wood","year":"1994","journal-title":"Pharmacol Ther"},{"key":"R8-3-20210208","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003088-199529010-00002","article-title":"Clinical pharmacokinetics and efficacy of renin inhibitors","volume":"29","author":"Rongen","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"R9-3-20210208","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.1993.74","article-title":"Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects","volume":"53","author":"Kleinbloesem","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R10-3-20210208","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.CIR.91.2.330","article-title":"Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects","volume":"91","author":"Menard","year":"1995","journal-title":"Circulation"},{"key":"R11-3-20210208","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R12-3-20210208","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200767120-00008","article-title":"Aliskiren: a review of its use in the management of hypertension","volume":"67","author":"Frampton","year":"2007","journal-title":"Drugs"},{"key":"R13-3-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R14-3-20210208","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"R15-3-20210208","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors","volume":"368","author":"Staessen","year":"2006","journal-title":"Lancet"},{"key":"R16-3-20210208","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004872-199404000-00012","article-title":"Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension","volume":"12","author":"Azizi","year":"1994","journal-title":"J Hypertens"},{"key":"R17-3-20210208","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0895-7061(95)00340-1","article-title":"Remikiren (Ro 42-5892): an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin\u2013angiotensin\u2013aldosterone system","volume":"9","author":"Himmelmann","year":"1996","journal-title":"Am J Hypertens"},{"key":"R18-3-20210208","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1161\/01.CIR.90.6.2748","article-title":"Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition","volume":"90","author":"Kiowski","year":"1994","journal-title":"Circulation"},{"key":"R19-3-20210208","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/clpt.1993.189","article-title":"Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension","volume":"54","author":"Rongen","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R20-3-20210208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00005344-199109000-00001","article-title":"Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans","volume":"18","author":"Camenzind","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"R21-3-20210208","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00005344-199503000-00001","article-title":"Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans","volume":"25","author":"MacFadyen","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"R22-3-20210208","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/00004872-199308000-00010","article-title":"Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension","volume":"11","author":"van den Meiracker","year":"1993","journal-title":"J Hypertens"},{"key":"R23-3-20210208","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.HYP.23.1.44","article-title":"Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans","volume":"23","author":"Fisher","year":"1994","journal-title":"Hypertension"},{"key":"R24-3-20210208","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.HYP.13.6.941","article-title":"Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans","volume":"13","author":"Delabays","year":"1989","journal-title":"Hypertension"},{"key":"R25-3-20210208","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/01.HYP.15.6.835","article-title":"Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension","volume":"15","author":"Boger","year":"1990","journal-title":"Hypertension"},{"key":"R26-3-20210208","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0009-9236(95)90160-4","article-title":"Renal vascular responses to renin inhibition with zankiren in men","volume":"57","author":"Fisher","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R27-3-20210208","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"R28-3-20210208","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","article-title":"Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption","volume":"15","author":"Azizi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R29-3-20210208","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2215\/CJN.00360107","article-title":"Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals","volume":"2","author":"Azizi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-3-20210208","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003088-200645110-00006","article-title":"Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with diabetes","volume":"45","author":"Zhao","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R31-3-20210208","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"R33-3-20210208","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1742-1241.2007.01473.x","article-title":"Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension","volume":"61","author":"Nussberger","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R34-3-20210208","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.clpt.6100495","article-title":"Pharmacokinetic\/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren","volume":"84","author":"Hong","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R35-3-20210208","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1046\/j.1365-2362.1999.00573.x","article-title":"Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension","volume":"29","author":"van Paassen","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"R36-3-20210208","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.V11101813","article-title":"Renin inhibition improves pressure natriuresis in essential hypertension","volume":"11","author":"van Paassen","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R39-3-20210208","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"R40-3-20210208","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"key":"R41-3-20210208","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.HYP.0000240064.19301.1b","article-title":"Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II","volume":"48","author":"Saris","year":"2006","journal-title":"Hypertension"},{"key":"R42-3-20210208","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/HYPERTENSIONAHA.107.101444","article-title":"Prorenin and renin-induced ERK 1\/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide","volume":"51","author":"Feldt","year":"2007","journal-title":"Hypertension"},{"key":"R43-3-20210208","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/HJH.0b013e3283060f2e","article-title":"Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren","volume":"26","author":"Schefe","year":"2008","journal-title":"J Hypertens"},{"key":"R44-3-20210208","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00109-008-0320-8","article-title":"PLZF and the (pro)renin receptor","volume":"86","author":"Schefe","year":"2008","journal-title":"J Mol Med"},{"key":"R45-3-20210208","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/ATVBAHA.108.164210","article-title":"Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells","volume":"28","author":"Batenburg","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R46-3-20210208","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ajh\/6.5.349","article-title":"Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension","volume":"6","author":"Kobrin","year":"1993","journal-title":"Am J Hypertens"},{"key":"R47-3-20210208","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00005344-199507000-00007","article-title":"Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension","volume":"26","author":"van Paassen","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"R48-3-20210208","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/15.5.637","article-title":"Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function","volume":"15","author":"van Paassen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R49-3-20210208","first-page":"133","article-title":"Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42-5892","volume":"8","author":"Viskoper","year":"1994","journal-title":"J Hum Hypertens"},{"key":"R50-3-20210208","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/01.HYP.18.1.22","article-title":"Ro 42-5892 is a potent orally active renin inhibitor in primates","volume":"18","author":"Fischli","year":"1991","journal-title":"Hypertension"},{"key":"R51-3-20210208","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/01.CIR.81.6.1768","article-title":"Assessment of renin dependency of hypertension with a dipeptide renin inhibitor","volume":"81","author":"Weber","year":"1990","journal-title":"Circulation"},{"key":"R52-3-20210208","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/0002-8703(91)90477-Y","article-title":"Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat","volume":"122","author":"Neutel","year":"1991","journal-title":"Am Heart J"},{"key":"R53-3-20210208","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1291\/hypres.29.997","article-title":"Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension","volume":"29","author":"Kushiro","year":"2006","journal-title":"Hypertens Res"},{"key":"R54-3-20210208","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R55-3-20210208","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"R56-3-20210208","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"R58-3-20210208","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1185\/030079908X280581","article-title":"Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis","volume":"24","author":"Chrysant","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R61-3-20210208","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"R62-3-20210208","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial","volume":"26","author":"Andersen","year":"2008","journal-title":"J Hypertens"},{"key":"R63-3-20210208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan","volume":"20","author":"Pool","year":"2007","journal-title":"Am J Hypertens"},{"key":"R64-3-20210208","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R65-3-20210208","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct renin inhibition with aliskiren in obese patients with arterial hypertension","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"R67-3-20210208","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-3565(25)19937-0","article-title":"Renal hemodynamic and excretory responses to renin inhibition induced by A-64662","volume":"252","author":"Verburg","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"R68-3-20210208","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00005344-199308000-00010","article-title":"Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs","volume":"22","author":"el Amrani","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"R69-3-20210208","first-page":"H897","article-title":"Renal vasodilatation after inhibition of renin or converting enzyme in marmoset","volume":"251","author":"Neisius","year":"1986","journal-title":"Am J Physiol"},{"key":"R70-3-20210208","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10557-008-6131-x","article-title":"A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes","volume":"22","author":"Major","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"R73-3-20210208","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179573.91016.3f","article-title":"Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats","volume":"46","author":"Pilz","year":"2005","journal-title":"Hypertension"},{"key":"R74-3-20210208","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00125-007-0795-9","article-title":"Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats","volume":"50","author":"Kelly","year":"2007","journal-title":"Diabetologia"},{"key":"R75-3-20210208","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","article-title":"Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-2)27 rats","volume":"52","author":"Feldman","year":"2008","journal-title":"Hypertension"},{"key":"R76-3-20210208","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3317\/jraas.2007.008","article-title":"Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes","volume":"8","author":"Dechend","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R78-3-20210208","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1681\/ASN.V111152","article-title":"Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies","volume":"11","author":"Segerer","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R80-3-20210208","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.108.123042","article-title":"Aliskiren accumulates in renin secretory granules and binds plasma prorenin","volume":"52","author":"Krop","year":"2008","journal-title":"Hypertension"},{"key":"R81-3-20210208","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","article-title":"Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans","volume":"117","author":"Fisher","year":"2008","journal-title":"Circulation"},{"key":"R83-3-20210208","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","article-title":"Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes","volume":"73","author":"Persson","year":"2008","journal-title":"Kidney Int"},{"key":"R84-3-20210208","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"R85-3-20210208","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R86-3-20210208","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00005344-198406060-00012","article-title":"Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure","volume":"6","author":"Sweet","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"R87-3-20210208","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00005344-199305000-00016","article-title":"Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction","volume":"21","author":"Mento","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"R88-3-20210208","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00005344-199202000-00003","article-title":"Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure","volume":"19","author":"Fitzpatrick","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"R89-3-20210208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00045391-199705000-00006","article-title":"Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats","volume":"4","author":"Zhang","year":"1997","journal-title":"Am J Ther"},{"key":"R90-3-20210208","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.2337\/db08-0805","article-title":"Intracellular angiotensin II production in diabetic rats is involved in cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis","volume":"57","author":"Singh","year":"2008","journal-title":"Diabetes"},{"key":"R91-3-20210208","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/HYPERTENSIONAHA.107.103143","article-title":"Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electric remodeling in a model of high human renin hypertension","volume":"51","author":"Fischer","year":"2008","journal-title":"Hypertension"},{"key":"R92-3-20210208","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1152\/ajpendo.00752.2007","article-title":"Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat","volume":"295","author":"Whaley-Connell","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R93-3-20210208","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0002-9149(91)90101-P","article-title":"Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure","volume":"67","author":"Neuberg","year":"1991","journal-title":"Am J Cardiol"},{"key":"R94-3-20210208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R95-3-20210208","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/eurheartj\/ehm605","article-title":"Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study","volume":"29","author":"de Simone","year":"2008","journal-title":"Eur Heart J"},{"key":"R96-3-20210208","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"R97-3-20210208","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/CIRCULATIONAHA.105.574822","article-title":"Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study","volume":"113","author":"Okin","year":"2006","journal-title":"Circulation"},{"key":"R98-3-20210208","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"R99-3-20210208","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.echo.2007.06.002","article-title":"Functional mitral regurgitation predicts prognosis independent of left ventricular systolic and diastolic indices in patients with ischemic heart disease","volume":"21","author":"Okura","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"R100-3-20210208","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.amjcard.2007.03.108","article-title":"Diagnostic usefulness and prognostic implications of the mitral E\/E' ratio in patients with heart failure and severe secondary mitral regurgitation","volume":"100","author":"Bruch","year":"2007","journal-title":"Am J Cardiol"},{"key":"R101-3-20210208","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Failure"},{"key":"R102-3-20210208","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ejheart.2007.09.002","article-title":"Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure","volume":"9","author":"Seed","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"R104-3-20210208","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1185\/03007990802336541","article-title":"Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren","volume":"24","author":"Rashid","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R105-3-20210208","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/sj.jhh.1002220","article-title":"A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension","volume":"21","author":"Strasser","year":"2007","journal-title":"J Hum Hypertens"},{"issue":"Suppl 2","key":"R106-3-20210208","first-page":"S22","article-title":"The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension","volume":"8","author":"Gradman","year":"2007","journal-title":"Rev Cardiovasc Med"},{"key":"R108-3-20210208","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/08037050701717014","article-title":"Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension","volume":"16","author":"Verdecchia","year":"2007","journal-title":"Blood Press"},{"key":"R109-3-20210208","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200746080-00003","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment","volume":"46","author":"Vaidyanathan","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R110-3-20210208","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270006294404","article-title":"Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment","volume":"47","author":"Vaidyanathan","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R111-3-20210208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R112-3-20210208","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","article-title":"Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis","volume":"1","author":"Weir","year":"2007","journal-title":"J Am Soc Hypertens"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200912000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:16:49Z","timestamp":1739434609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200912000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":98,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3283310f92","relation":{},"ISSN":["0263-6352"],"issn-type":[{"type":"print","value":"0263-6352"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}